195 related articles for article (PubMed ID: 36918834)
21. Prognostic Value of Platelet-to-Lymphocyte Ratio, Neutrophil-to-Lymphocyte Ratio, and Lymphocyte-to-White Blood Cell Ratio in Colorectal Cancer Patients Who Received Neoadjuvant Chemotherapy.
Jia W; Yuan L; Ni H; Xu B; Zhao P
Technol Cancer Res Treat; 2021; 20():15330338211034291. PubMed ID: 34308689
[TBL] [Abstract][Full Text] [Related]
22. [Comparison of short-term efficacy and perioperative safety between neoadjuvant therapy and total neoadjuvant therapy in patients with locally advanced rectal cancer].
Zhai ZW; Zhang KN; Wang C; Han JG; Ma HC; Wei GH; Yang Y; Wang ZJ
Zhonghua Wei Chang Wai Ke Za Zhi; 2020 Mar; 23(3):274-280. PubMed ID: 32192307
[No Abstract] [Full Text] [Related]
23. Neoadjuvant chemoradiotherapy plus postoperative adjuvant XELOX chemotherapy versus postoperative adjuvant chemotherapy with XELOX regimen for local advanced gastric cancer-A randomized, controlled study.
Wang F; Qu A; Sun Y; Zhang J; Wei B; Cui Y; Liu X; Tian W; Li Y
Br J Radiol; 2021 Aug; 94(1124):20201088. PubMed ID: 34260297
[TBL] [Abstract][Full Text] [Related]
24. [Application of regional arterial infusion chemotherapy in short-term neoadjuvant chemotherapy for advanced gastric cancer].
Wu Z; Zhu W; Cao Q; Chen Z; Wu X; Chen C; Xu Z; Li W; Yao X; Liu F
Zhonghua Wei Chang Wai Ke Za Zhi; 2014 Nov; 17(11):1092-5. PubMed ID: 25421767
[TBL] [Abstract][Full Text] [Related]
25. Impact of Neoadjuvant Chemotherapy on Postoperative Morbidity after Gastrectomy for Gastric Cancer.
Téoule P; Trojan J; Bechstein W; Woeste G
Dig Surg; 2015; 32(4):229-37. PubMed ID: 25966823
[TBL] [Abstract][Full Text] [Related]
26. [Efficacy of neoadjuvant chemotherpy in patients with locally advanced gastric cancer].
Wang Y; Liu TS; Zhuang RY; Cui YH; Wang ZM; Yu YY; Hou J; Sun YH; Shen KT; Shen ZB
Zhonghua Wei Chang Wai Ke Za Zhi; 2013 Feb; 16(2):166-9. PubMed ID: 23446480
[TBL] [Abstract][Full Text] [Related]
27. [Postoperative complications and their influence on the prognosis factors in gastric cancer patients receiving neoadjuvant treatment].
Wang TB; Mao QK; Zhang XJ; Zhou H; Guo CG; Chen YT; Zhao DB
Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Feb; 24(2):160-166. PubMed ID: 33508922
[No Abstract] [Full Text] [Related]
28. [Prognostic analysis of neoadjuvant chemotherapy for locally advanced gastric cancer with propensity score matching method].
Peng L; Yang W; Zhang Z; Zhi C; Zhou X; Liu H; Hua Y
Zhonghua Wei Chang Wai Ke Za Zhi; 2018 Oct; 21(10):1148-1153. PubMed ID: 30370514
[TBL] [Abstract][Full Text] [Related]
29. Early myelostimulation in patients with locally advanced gastric cancer after fluorouracil plus platinum-based neoadjuvant chemotherapy is related to poor prognosis.
Liu Y; Cao Y; Xiao L; Wang H
Cancer Chemother Pharmacol; 2021 May; 87(5):701-710. PubMed ID: 33611625
[TBL] [Abstract][Full Text] [Related]
30. Surgical outcomes in patients with locally advanced gastric cancer treated with S-1 and oxaliplatin as neoadjuvant chemotherapy.
Feng D; Leong M; Li T; Chen L; Li T
World J Surg Oncol; 2015 Jan; 13():11. PubMed ID: 25634099
[TBL] [Abstract][Full Text] [Related]
31. Efficacy of neoadjuvant chemotherapy with docetaxel, cisplatin and S-1 for resectable locally advanced gastric cancer.
Migita K; Nashimoto A; Yabusaki H; Matsuki A; Aizawa M
Int J Clin Oncol; 2016 Feb; 21(1):102-9. PubMed ID: 26017926
[TBL] [Abstract][Full Text] [Related]
32. Neoadjuvant FLOT versus SOX phase II randomized clinical trial for patients with locally advanced gastric cancer.
Sah BK; Zhang B; Zhang H; Li J; Yuan F; Ma T; Shi M; Xu W; Zhu Z; Liu W; Yan C; Li C; Liu B; Yan M; Zhu Z
Nat Commun; 2020 Nov; 11(1):6093. PubMed ID: 33257672
[TBL] [Abstract][Full Text] [Related]
33. [Application of short-course radiotherapy with total neoadjuvant therapy in the treatment of middle and low rectal cancer].
Chen CJ; Yang CK; Jian JL; Guan S; Xie MM
Zhonghua Yi Xue Za Zhi; 2023 Jan; 103(4):271-277. PubMed ID: 36660788
[No Abstract] [Full Text] [Related]
34. The validity of neoadjuvant chemotherapy with paclitaxel plus S-1 is not inferior to that of SOX regimen for locally advanced gastric cancer: an observational study.
Zhang C; Wu B; Yang H; Yao Z; Zhang N; Tan F; Liu M; Xu K; Chen L; Xing J; Cui M; Su X
BMC Cancer; 2022 Nov; 22(1):1223. PubMed ID: 36443694
[TBL] [Abstract][Full Text] [Related]
35. Association of neutrophil/lymphocyte ratio and platelet/lymphocyte ratio with ER and PR in breast cancer patients and their changes after neoadjuvant chemotherapy.
Xu J; Ni C; Ma C; Zhang L; Jing X; Li C; Liu Y; Qu X
Clin Transl Oncol; 2017 Aug; 19(8):989-996. PubMed ID: 28247194
[TBL] [Abstract][Full Text] [Related]
36. Long-term survival outcome of locally advanced gastric cancer patients who achieved a pathological complete response to neoadjuvant chemotherapy.
Guo F; Xiang X; Huang Y; Chen A; Ma L; Zhu X; Abdulla Z; Jiang W; Li J; Li G
Int J Clin Oncol; 2023 Sep; 28(9):1158-1165. PubMed ID: 37318644
[TBL] [Abstract][Full Text] [Related]
37. Pathologic Complete Response After Gastric Artery Chemoembolization Combined With Tislelizumab for Neoadjuvant Therapy of Locally Advanced Gastric Cancer: A Case Report.
Lin Y; Chen Y; Lin S; Zheng J; Zhang X; Gan L
J Immunother; 2024 Apr; 47(3):101-105. PubMed ID: 38037229
[TBL] [Abstract][Full Text] [Related]
38. [Effect of neoadjuvant chemotherapy on nutritional status of locally advanced gastric cancer].
Deng G; Qu J; Zhai S; Shi Y; Wang X
Zhonghua Wei Chang Wai Ke Za Zhi; 2018 Mar; 21(3):331-335. PubMed ID: 29577223
[TBL] [Abstract][Full Text] [Related]
39. Neoadjuvant Nivolumab Plus Ipilimumab and Adjuvant Nivolumab in Localized Deficient Mismatch Repair/Microsatellite Instability-High Gastric or Esophagogastric Junction Adenocarcinoma: The GERCOR NEONIPIGA Phase II Study.
André T; Tougeron D; Piessen G; de la Fouchardière C; Louvet C; Adenis A; Jary M; Tournigand C; Aparicio T; Desrame J; Lièvre A; Garcia-Larnicol ML; Pudlarz T; Cohen R; Memmi S; Vernerey D; Henriques J; Lefevre JH; Svrcek M
J Clin Oncol; 2023 Jan; 41(2):255-265. PubMed ID: 35969830
[TBL] [Abstract][Full Text] [Related]
40. Peripheral Venous Blood Platelet-to-Lymphocyte Ratio (PLR) for Predicting the Survival of Patients With Gastric Cancer Treated With SOX or XELOX Regimen Neoadjuvant Chemotherapy.
Chen L; Hao Y; Cong X; Zou M; Li S; Zhu L; Song H; Xue Y
Technol Cancer Res Treat; 2019 Jan; 18():1533033819829485. PubMed ID: 30760114
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
